Novartis adds another Cosentyx approval with FDA nod

The FDA on 21 January gave its blessing to Novartis to market Cosentyx (secukinumab) as a treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.